Navigation Links
Hovione Buys Drug Manufacturing Facility in China
Date:3/6/2008

LOURES, Portugal, March 6 /PRNewswire/ -- Hovione announces that it has purchased 75% of Hisyn Pharmaceutical Co. Limited. The Zhejiang provincial authorities have already issued the necessary business license and the joint venture (JV) is now operational.

The acquisition provides Hovione with significant additional drug substance manufacturing production capacity and strengthens its 20 year presence in China. The acquisition includes both development labs in Shanghai and an active pharmaceutical ingredient (API) plant occupying 22,000 square meters. on a 22 acre plot employing 181 staff. Hovione's relationship with Hisyn started with the supply of intermediates, but this factory, which was commissioned in 2005 from a greenfield site, will now produce Hovione's two largest volume products.

"Hisyn represents an opportunity to both increase our manufacturing capacity and ensure a sustainable cost advantage. We find it important to provide our current customers with an assurance of competitive supply over the long run; and in addition we want to have a strong presence in new markets, such as Brazil, India and China, where price is decisive" said Miguel Calado, CFO.

The negotiation and the acquisition processes moved smoothly in part due to the experience Hovione has built in China over the last 3 decades. The Macau plant, with 5 previous FDA inspections and more than 10 years of contract manufacturing relationships in China, has enabled Hovione to effectively bridge cultures with China in every dimension: language, GMP, culture and business practices.

Luis Gomes, Vice President of Generics, and responsible for the investment and integration process added: "When we first came to the Canton fair in 1979 we were buying raw-materials that would be processed in Macau or in Portugal. For many years we felt we'd be better off being an important client of Chinese plants through contract manufacturing deals, because at that time there many JVs going very wrong. Now is the right time for Hovione to acquire infrastructure in China and tap into a growing market and leverage China's manufacturing abilities. We are planning to invest further monies in 2008 to effectively double Hisyn's manufacturing capacity".

Hovione is an international group specializing in the development and compliant production of active pharmaceutical ingredients, serving exclusively the pharmaceutical industry. In 2006 it had sales of US$94 million (Euro 70 million). With almost 50-year in process development, quality standards and advanced particle design technologies, Hovione offers APIs for all drug delivery systems, from oral to injectable and from inhalation to topical applications. With FDA inspected plants in Europe, the Far East and New Jersey, Hovione is committed to the highest levels of service and quality. Specializing in complex chemistry, Hovione offers services related to the development and manufacture of either a new chemical entity (NCE) for an exclusive contract manufacturing partner or an existing API for an off-patent product.

For further information about Hovione, please visit the Hovione site at http://www.hovione.com or contact Corporate Communications:

Isabel Pina,

+351-21-982-9362,

e-mail: hello@hovione.com.


'/>"/>
SOURCE Hovione
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
2. Middle East Pharma Manufacturing/Biotech is Ready to Boom
3. SAFC Expands European Commercial Manufacturing and Storage Capacities With $10 Million Investment
4. Hyaluron Contract Manufacturing Named a 2007 Economic Impact Award Finalist
5. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
6. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
7. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
8. Genzyme Begins Major Expansion of Boston Manufacturing Facility
9. SAFC Supports Potent API Conjugate Manufacturing With New St. Louis Production Suite
10. PacificGMP Announces Agreement with BD Biosciences for Cell Banking and cGMP Antibody Manufacturing
11. Thermo Fisher Scientific to Expand Manufacturing Operation for Single-Use Bioprocessing Containers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2017)... ... June 26, 2017 , ... NDA ... former Associate Director of Product Development R&D at Allergan and CMC expert with ... both start-up and established biopharma companies, has joined the firm as an Expert ...
(Date:6/26/2017)... ... June 26, 2017 , ... The Workgroup for Electronic Data ... to create efficiencies in healthcare information exchange and a statutory advisor to the U.S. ... of the federal Office of the National Coordinator for Health Information Technology, will deliver ...
(Date:6/23/2017)... ... June 23, 2017 , ... Biova, LLC., the leader in ... Biova’s Board of Directors. Dr. Henig will bring a wealth of scientific experience in ... as the Chief Technical and Scientific Officer of four major global companies in the ...
(Date:6/23/2017)... ... 23, 2017 , ... Ken Hanson, a medical imaging research scientist at Los ... selected as this year’s recipients of two top awards from SPIE, the international ... other honorees to accept their awards at a banquet in San Diego, California, on ...
Breaking Biology Technology:
(Date:3/27/2017)... ROCKVILLE CENTRE, N.Y. , March 27, 2017 ... by Healthcare Information and Management Systems Society (HIMSS) ... Analytics Outpatient EMR Adoption Model sm . In ... top 12% of U.S. hospitals using an electronic ... recognized CHS for its high level of EMR ...
(Date:3/24/2017)... Mar 24, 2017 Research and Markets has ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... at a CAGR of around 15.1% over the next decade to ... report analyzes the market estimates and forecasts for all the given ...
(Date:3/23/2017)... 2017 Research and Markets has announced the ... Trends - Industry Forecast to 2025" report to their offering. ... The Global ... of around 8.8% over the next decade to reach approximately $14.21 ... market estimates and forecasts for all the given segments on global ...
Breaking Biology News(10 mins):